106 related articles for article (PubMed ID: 9873112)
1. Bioisosteric approach in the design of new dopaminergic/serotonergic ligands.
Soskić V; Joksimović J
Curr Med Chem; 1998 Dec; 5(6):493-512. PubMed ID: 9873112
[TBL] [Abstract][Full Text] [Related]
2. New substituted 2-methylthiomethyl- and 2-methylsulphinylmethylenebenzimidazoles with D2/5-HT1A activity.
Kostić-Rajacić S; Soskić V; Joksimović J
Pharmazie; 1998 Jul; 53(7):438-41. PubMed ID: 9699220
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of several substituted phenylpiperazines behaving as mixed D2/5HT1A ligands.
Dukić S; Kostić-Rajacić S; Dragović D; Soskić V; Joksimović J
J Pharm Pharmacol; 1997 Oct; 49(10):1036-41. PubMed ID: 9364416
[TBL] [Abstract][Full Text] [Related]
4. Mixed dopaminergic/serotonergic properties of several 2-substituted 4-[2-(5-benzimidazole)ethyl]-1-arylpiperazines.
Kostic-Rajacic S; Soskic V; Joksimovic J
Arch Pharm (Weinheim); 1998 Jan; 331(1):22-6. PubMed ID: 9507698
[TBL] [Abstract][Full Text] [Related]
5. Structure-affinity relationship studies on D-2/5-HT1A receptor ligands. 4-(2-Heteroarylethyl)-1-arylpiperazines.
Dukić S; Vujović M; Soskić V; Joksimović J
Arzneimittelforschung; 1997 Mar; 47(3):239-43. PubMed ID: 9105540
[TBL] [Abstract][Full Text] [Related]
6. Introduction of a methyl group in alpha- or beta-position of 1-heteroarylethyl-4-phenylpiperazines affects their dopaminergic/serotonergic properties.
Roglic G; Andric D; Kostic-Rajacic S; Dukic S; Soskic V
Arch Pharm (Weinheim); 2001 Dec; 334(12):375-80. PubMed ID: 11852532
[TBL] [Abstract][Full Text] [Related]
7. Investigation of mixed D2/5-HT1A activity of N-heteroarylmethyl-N-phenylpiperazines, N-heteroarylethyl-N-phenylpiperazines and N-heteroarylpropyl-N-phenylpiperazines.
Roglić G; Dukić-Stefanović S; Andrić D; Kostić-Rajacić S; Soskić V
Pharmazie; 2001 Oct; 56(10):803-7. PubMed ID: 11683128
[TBL] [Abstract][Full Text] [Related]
8. Electrostatic surface potential calculation on several new halogenated benzimidazole-like dopaminergic ligands.
Sukalović V; Andrić D; Roglić G; Kostić-Rajaccić S; Soskić V
Arch Pharm (Weinheim); 2004 Jul; 337(7):376-82. PubMed ID: 15237387
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and dopaminergic features of six novel 3-arylpiperidines.
Kostic-Rajacic A; Soskic V; Joksimovic J
Boll Chim Farm; 1998 Nov; 137(10):417-21. PubMed ID: 10025971
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of Arylpiperazine Serotonergic/Dopaminergic Ligands with Neuroprotective Properties.
Mastromarino M; Niso M; Abate C; Proschak E; Dubiel M; Stark H; Castro M; Lacivita E; Leopoldo M
Molecules; 2022 Feb; 27(4):. PubMed ID: 35209087
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and dopaminergic properties of 3- and 4-substituted 1-[2-[5-(1H-benzimidazole-2-thione)]ethyl]piperidines and related compounds.
Dukic S; Kostic-Rajacic S; Soskic V; Joksimovic J
Arch Pharm (Weinheim); 1997; 330(1-2):25-8. PubMed ID: 9112811
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of N-n-propyl-N-(2-arylethyl)-5-(1H-benzimidazol-2-thione)-eth ylamines and related compounds as potential dopaminergic ligands.
Soskic V; Dukić S; Dragović D; Joksimović J
Arzneimittelforschung; 1996 Aug; 46(8):741-6. PubMed ID: 9125270
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and properties of several heterocyclic dopaminergic ligands.
Kostić S; Soskić V; Joksimović J
Arzneimittelforschung; 1994 Jun; 44(6):697-702. PubMed ID: 7914413
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in vitro pharmacological evaluation of novel 2-hydroxypropyl-4-arylpiperazine derivatives as serotoninergic ligands.
Fiorino F; Magli E; Severino B; Corvino A; Ciano A; Perissutti E; Frecentese F; Massarelli P; Nencini C; Santagada V; Caliendo G
Arch Pharm (Weinheim); 2014 Oct; 347(10):698-706. PubMed ID: 25113046
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and binding properties of several new dopaminergic ligands.
Tuce Z; Soskić V; Joksimović J
Drug Des Discov; 1994 Jun; 11(4):251-8. PubMed ID: 7727678
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of N,N-di-n-propyl-5,6,7,8-tetrahydro-1 H-benz[f]benzimidazol-6-yl-amine and related congeners as dopaminergic ligands.
Dragović D; Soskić V; Joksimović J
Pharmazie; 1995 Oct; 50(10):678-80. PubMed ID: 7501691
[TBL] [Abstract][Full Text] [Related]
17. Computer imaging and analysis of dopamine (D2) and serotonin (S2) binding sites in rat basal ganglia or neocortex labeled by [3H]spiroperidol.
Altar CA; Kim H; Marshall JF
J Pharmacol Exp Ther; 1985 May; 233(2):527-38. PubMed ID: 3889277
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic and serotonergic activities of imidazoquinolinones and related compounds.
Moon MW; Morris JK; Heier RF; Chidester CG; Hoffmann WE; Piercey MF; Althaus JS; Von Voigtlander PF; Evans DL; Figur LM
J Med Chem; 1992 Mar; 35(6):1076-92. PubMed ID: 1348089
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of a series of 6-substituted-2-pyridinylmethylamine derivatives as novel, high-affinity, selective agonists at 5-HT1A receptors.
Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C
J Med Chem; 1998 Dec; 41(25):5070-83. PubMed ID: 9836623
[TBL] [Abstract][Full Text] [Related]
20. An overview on benzylisoquinoline derivatives with dopaminergic and serotonergic activities.
Cabedo N; Berenguer I; Figadère B; Cortes D
Curr Med Chem; 2009; 16(19):2441-67. PubMed ID: 19601791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
